HemaSphere (Jun 2022)
P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
- C. Harrison,
- P. Bose,
- R. Mesa,
- A. Gerds,
- S. Oh,
- J.-J. Kiladjian,
- V. García-Gutierrez,
- A. Vannucchi,
- C. Scheid,
- M. Sobas,
- S. Verstovsek,
- S. Buckley,
- K. Roman-Torres,
- J. Mascarenhas
Affiliations
- C. Harrison
- 1 Guy’s and St Thomas’ NHS Trust, London, United Kingdom
- P. Bose
- 2 The University of Texas MD Anderson Cancer Center, Houston, TX
- R. Mesa
- 3 UT Health San Antonio Cancer Center, San Antonio, TX
- A. Gerds
- 4 Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
- S. Oh
- 5 Washington University School of Medicine, St. Louis, MO, United States of America
- J.-J. Kiladjian
- 6 Hôpital Saint-Louis, Université de Paris, Paris, France
- V. García-Gutierrez
- 7 Hospital Universitario Ramón y Cajal, Madrid, Spain
- A. Vannucchi
- 8 Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy
- C. Scheid
- 9 University of Cologne, Cologne, Germany
- M. Sobas
- 10 Wroclaw Medical University, Wroclaw, Poland
- S. Verstovsek
- 2 The University of Texas MD Anderson Cancer Center, Houston, TX
- S. Buckley
- 11 CTI BioPharma, Seattle, WA
- K. Roman-Torres
- 11 CTI BioPharma, Seattle, WA
- J. Mascarenhas
- 12 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
- DOI
- https://doi.org/10.1097/01.HS9.0000847144.39334.7c
- Journal volume & issue
-
Vol. 6
pp. 959 – 960
Abstract
No abstracts available.